Stem cell transplantation for neuroblastoma

Fish, Jonathan D.; Grupp, Stephan A.

doi:10.1038/sj.bmt.1705929

Cited by 69 publications

(59 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent advances in stem cell research, such as the possibility of obtaining pluripotent stem cells from adult tissues (Takahashi and Yamanaka, 2006) and their capacity to differentiate in vitro into almost all kinds of tissues, have generated many therapeutic expectations (Atala, 2007;Fish and Grupp, 2008). However, as this work shows, the risk of generating a tumour after these transplants is a real possibility, especially when employing cultured stem cells.…”

Section: Discussionmentioning

confidence: 77%

Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Carcinoma in situ (CIS) of the testis is considered to be a precancerous germinal cell lesion, but the precise cellular and molecular mechanisms underlying transformation of CIS into invasive pluripotent cancer cells remain to be elucidated. Moreover, a satisfactory animal model for the experimental study of germinal tumours has not been developed to date. METHODS: We have developed a tumour model that involves the microinjection of green fluorescent protein-labelled embryonic stem (ES) cells (which are functionally equivalent to CIS cells) into syngenic mouse seminiferous tubules, a unique cell microenvironment in which germinal cells mature and CIS arise. To characterise the vascularisation of teratocarcinomas, which arise after cell transplant, we used immunohistochemistry, together with a qualitative and quantitative analysis of scanning electron microscopy images of corrosion casting samples. RESULTS: Embryonic stem cells transplanted into seminiferous tubules did not differentiate into germinal cells, but rather they behaved as invasive embryonal carcinoma (EC) stem cells. The vascular pattern of the experimental teratocarcinomas showed a highly disorganised architecture, and some of the neoplastic capillaries were derived, at least in part, from the original transplanted ES cells. CONCLUSION: The transplantation of pluripotent ES cells into seminiferous tubules efficiently recapitulates the early stages of development of teratocarcinomas. Consequently, this method constitutes a novel in vivo model to study the mechanisms of invasion and progression of experimental germinal tumours.

show abstract

Section: Discussionmentioning

confidence: 77%

Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Stem cells to be used for ASCR are typically harvested after 2-3 cycles of induction chemotherapy. Peripheral blood has become the preferred source of these stem cells because of easier collection, higher yield, lower incidence of tumor cell contamination, and faster blood count recovery [79,80]. Continued concerns regarding the potential for circulating neuroblastoma tumor cell contamination led to studies evaluating the efficacy of stem cell purging prior to reinfusion for children with high-risk neuroblastoma.…”

Section: Consolidationmentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

326

258

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

“…1 from a practical clinical point of view was the fact that the initial very good partial remission achieved with CELYVIR was followed by the current most accepted consolidation therapy for good responder NB stage IV. 34 It has been reported that the combination therapy (virotherapy þ chemotherapy) resulted in synergistic efficacy in some patients. 35 This patient might be a good example on how systemic virotherapy can be used in combination with standard multimodal protocols for metastatic cancers.…”

Section: Pre-celyvirmentioning

confidence: 99%

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study

et al. 2010

View full text Add to dashboard Cite

Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells (MSCs) may allow the use of MSCs as cellular vehicles for targeted delivery. In this work, we study the safety and the efficacy of infusing autologous MSCs infected with ICOVIR-5, a new oncolytic adenovirus, for treating metastatic neuroblastoma. Four children with metastatic neuroblastoma refractory to front-line therapies received several doses of autologous MSCs carrying ICOVIR-5, under an approved preliminary study. The tolerance to the treatment was excellent. A complete clinical response was documented in one case, and the child is in complete remission 3 years after this therapy. We postulate that MSCs can deliver oncolytic adenoviruses to metastatic tumors with very low systemic toxicity and with beneficial antitumor effects.

show abstract

Stem cell transplantation for neuroblastoma

Cited by 69 publications

References 44 publications

Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules

Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules

Overview and recent advances in the treatment of neuroblastoma

Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study

Contact Info

Product

Resources

About